<DOC>
	<DOC>NCT01153984</DOC>
	<brief_summary>This open-label, single-arm, multi-center study will evaluate the effect of Tarceva (erlotinib) on progression-free survival and the incidence and type of biomarkers in patients with advanced and/or metastatic non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) positive mutations. Eligible patients will receive Tarceva 150mg po daily. The anticipated time on study treatment is until progression or unacceptable toxicity.</brief_summary>
	<brief_title>A Study of Tarceva (Erlotinib) in Patients With Advanced and/or Metastatic Non-small Cell Lung Cancer With EGFR Positive Mutation (BIOTEC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patients, &gt;=18 years of age Histological documented adenocarcinoma, locally advanced stage IIIB, metastatic stage IV or recurrent nonsquamous nonsmall cell lung cancer (NSCLC) Eastern Cooperative Oncology Group (ECOG) performance status 01 Life expectancy &gt;=12 weeks Evidence of disease with at least one measurable disease criteria as evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) Adequate haematological, liver and renal function Known hypersensitivity to erlotinib or any of its excipients Squamous nonsmall cell or small cell tumors or absence of histological report Neoadjuvant/adjuvant chemotherapy within 6 months prior to enrolment Prior exposure to inhibitors of Epidermal Growth Factor Receptor (EGFR) Prior chemotherapy or treatment with another systemic anticancer agent for the treatment of the patient's current stage of disease Any significant ophthalmologic abnormality, especially severe dry eye syndrome, keratoconjunctivitis sicca, Sj√∂grens syndrome, severe exposure keratitis or any other disorder likely to increase the risk of corneal epithelial lesions Radical radiotherapy with curative intent within 28 days prior to enrolment Any active noncontrolled systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>